Scribeable vs Heidi Health:
Considering Heidi? Here is a factual look at how Scribeable differs. Both offer a free tier, so this comparison is about published dollar pricing, US coding depth, and capital structure.
120+ clinicians · 2,600+ notes generated — real counters, no composites (scribeable.ai/transparency)
Why Physicians Switch from Heidi Health
No dollar amounts on the public pricing page — heidihealth.com/pricing shows tiers and features, but seeing a price requires signing up or contacting the team
US revenue tooling (HCC capture, MIPS scoring) is not advertised on heidihealth.com — worth confirming directly with Heidi if US billing depth matters to your practice
VC-backed: a $65M Series B led by Point72 sets the growth expectations Heidi answers to
Built Around US Billing, or Alongside It
Heidi's site advertises compliance across five markets — HIPAA in the US, GDPR, and regional requirements in Australia/NZ, Canada, and the UK. What it does not advertise is US revenue tooling: HCC capture or MIPS quality-measure scoring. Scribeable is built for exactly that — an 8,400+ entry HCC crosswalk and MIPS measures scored inside the note, because for a US practice, the note is where risk-adjusted revenue lives or dies.
Publish the Price or Don't
Heidi's pricing page names its tiers — Free, Clinician, Practice — and lists what each includes. What it doesn't show is a price: no dollar amounts appear on the public page as of July 2026. Scribeable publishes its rates: $39/month for Lite, $79/month for Pro, with a 14-day free trial and no credit card to start. You can see the price before you ever sign up.
A Bootstrapped Cap Table Is a Structural Fact, Not a Slogan
Heidi announced a $65M USD Series B led by Point72 Private Investments — on its own blog — bringing total funding to roughly $96M. Scribeable has raised $0 in outside capital. That difference doesn't say anything about either company's intentions today — it says something about who each company answers to at the next board meeting.
Same Patient. Same Encounter.
See why physicians say Scribeable notes are “actually usable” — with integrated risk scores, billing codes, and clinical reasoning that typical AI scribes simply don’t generate.
HPI
62 y/o male presents with chest pain for 2 hours. Substernal, pressure-like, radiating to left arm. Associated with diaphoresis and shortness of breath. Pain started while climbing stairs. Patient has history of HTN, DM2, and hyperlipidemia. Takes lisinopril, metformin, and atorvastatin. Denies recent illness or trauma.
Assessment & Plan
*Note examples are illustrative representations based on common AI documentation patterns. “Typical AI Scribe” represents composite characteristics of standard tools and does not depict any specific product. Patient scenarios are entirely fictional. Clinical notes should always be reviewed by a licensed provider.
AI Medical Scribe Note Quality Comparison
Scribeable produces clinically enriched notes with integrated risk calculators (HEART Score, CHA₂DS₂-VASc, Wells PE, PHQ-9, Caprini VTE), automated billing code optimization (E&M levels, HCC/RAF capture, CPT codes), dangerous diagnosis exclusion documentation, evidence-based prescribing citations, CMS compliance for operative reports, HEDIS care gap tracking, and MIPS quality measure documentation. Typical AI scribes produce basic notes without these advanced clinical features.
ED Chest Pain: 62-year-old male presenting with substernal chest pressure, diaphoresis, and exertional dyspnea
HPI: 62 y/o male presents with 2 hours of substernal chest pressure, rated 8/10, radiating to left arm and jaw. Onset during exertion (climbing stairs). Associated with diaphoresis and exertional dyspnea. Pressure-like quality, unrelieved by rest. No pleuritic component, no positional variation, no reproducibility with palpation. Risk factors: HTN (10 years), DM2 (8 years), hyperlipidemia, 30-pack-year smoking history (quit 5 years ago), family history of MI (father at age 58). Current medications: lisinopril 20mg daily, metformin 1000mg BID, atorvastatin 40mg daily. Denies cocaine use, recent immobilization, or prior VTE.
Assessment & Plan: 1. Acute Chest Pain — High-risk presentation HEART Score: 7 (High Risk) - History: moderately suspicious (2), EKG: non-specific ST changes (1), Age: >65 (2), Risk factors: ≥3 (2), Troponin: pending initial (0) - Risk stratification: >12% 6-week MACE event rate → full ACS workup - Serial troponins q3h, 12-lead EKG (initial + repeat at 60 min) - ASA 325mg PO administered, heparin drip per ACS protocol - Cardiology consulted for probable cath lab activation Dangerous Diagnosis Exclusion: - STEMI: No ST elevation on initial EKG — serial monitoring - Aortic dissection: No tearing quality, no pulse differential, no mediastinal widening on CXR - PE: Low pretest probability (Wells PE: 1.5) — no immobilization, no prior VTE, no hemoptysis 2. Hypertension — BP 168/94 on arrival, improved to 142/88 post-NTG - Continue home lisinopril, recheck prior to disposition 3. DM2 — Glucose 186 on arrival - Hold metformin (contrast exposure risk), sliding scale insulin PRN
Cardiology Consult: 71-year-old female with new-onset atrial fibrillation and decompensated heart failure
HPI: 71 y/o female with known HFrEF (EF 35% on TTE 6 months ago), HTN, DM2, and CKD Stage 3a (baseline Cr 1.4), consulted for new-onset atrial fibrillation with RVR. Progressive exertional dyspnea (NYHA II → IV over 2 weeks), 3-pillow orthopnea (new), PND, and 4+ pitting edema to knees bilaterally. Weight gain of 8 lbs over 2 weeks. Triggers explored: dietary indiscretion (holiday meals), medication non-adherence (ran out of furosemide 10 days ago). No prior AF history, no palpitations previously. Denies chest pain, syncope, or presyncope.
Assessment & Plan: Reason for Consult: New-onset atrial fibrillation with RVR in setting of acute decompensated HFrEF. Requesting Service: Internal Medicine (Dr. Patel) 1. New-onset Atrial Fibrillation with RVR CHA₂DS₂-VASc Score: 5 (Female sex, age ≥75, HTN, DM, HF) - Stroke risk: 6.7%/year → strong anticoagulation indication - Rate control: avoid diltiazem (negative inotropy in HFrEF) → amiodarone 150mg IV bolus then 1mg/min × 6h - Anticoagulation: apixaban 5mg BID (preferred over warfarin given age + fall risk) - TEE prior to any cardioversion attempt if AF duration uncertain - HAS-BLED: 2 (HTN, age) — acceptable bleeding risk 2. Acute Decompensated Heart Failure (ADHF) NYHA Functional Class: IV (dyspnea at rest) - IV furosemide 80mg BID (2.5× home oral dose), net negative 1-1.5L/day - Carvedilol held (acute decompensation), restart when euvolemic - Add sacubitril/valsartan when stable (PARADIGM-HF indication: EF ≤40% on ACEi) - BNP trend: 1,840 → monitor for response to diuresis 3. CKD Stage 3a — Cr 1.4 (baseline), monitor with aggressive diuresis - KDIGO risk: moderate — monitor Cr/K daily with diuresis
Operative Note: Right total knee arthroplasty in 68-year-old male with severe tricompartmental osteoarthritis
Operative Note: Preoperative Diagnosis: Right knee severe tricompartmental osteoarthritis (Kellgren-Lawrence Grade IV) Postoperative Diagnosis: Same Procedure: Right total knee arthroplasty Surgeon: Dr. James Morrison (attending — present and scrubbed for entire case) Assistant: Dr. Chen (PGY-4) Anesthesia: Spinal with sedation (Dr. Rivera) Implants: Smith & Nephew Legion CR, Size 5 femoral / Size 4 tibial / 10mm poly insert EBL: 150 mL Tourniquet Time: 62 minutes (pneumatic, 275 mmHg) Specimens: Femoral and tibial bone cuts — to pathology Complications: None Findings: Severe tricompartmental degenerative changes with exposed subchondral bone medially, grade III chondromalacia laterally, intact PCL
Post-Operative Plan: 1. Weight Bearing: WBAT right LE with front-wheeled walker 2. DVT Prophylaxis: Enoxaparin 40mg SQ daily × 14 days + mechanical (SCDs while inpatient) 3. Pain: Multimodal — scheduled acetaminophen 1g Q6h, meloxicam 15mg daily, tramadol 50mg Q6h PRN (max 14 days) 4. Antibiotics: Ancef 2g IV × 24h post-op 5. PT: Initiate POD0 PM — CPM machine, active/passive ROM, gait training 6. Follow-up: 2 weeks (staple removal + wound check), 6 weeks (X-ray + ROM assessment) 7. VTE Risk: Caprini Score 7 (High Risk) — extended pharmacologic prophylaxis indicated
Primary Care: 55-year-old female Medicare Advantage patient with DM2, HTN, depression, and overdue preventive care
HPI: 55 y/o female Medicare Advantage patient presenting for chronic disease management follow-up. Last visit 3 months ago. Diabetes (DM2, 8 years): A1c 8.2% (up from 7.6%), reports adherence but dietary indiscretion during holidays. Home glucose logs show fasting 140-180 range. No hypoglycemic episodes. Denies polyuria, polydipsia, vision changes, or foot numbness. Last diabetic eye exam: 14 months ago (overdue). Last podiatry visit: never. Hypertension (12 years): Home BP readings averaging 135-145/85-90. Taking lisinopril 20mg daily consistently. Depression (MDD, recurrent): PHQ-9 score today: 14 (moderately severe). Persistent low mood, anhedonia, poor sleep (initial insomnia), decreased concentration. On sertraline 50mg × 6 months with partial response. Denies SI/HI, denies alcohol or substance use. Columbia Suicide Severity: negative for ideation and behavior.
Assessment & Plan: 1. DM2, Uncontrolled (A1c 8.2%) — HCC 19 - Add empagliflozin 10mg daily (SGLT2i — CV and renal benefit, EMPA-REG OUTCOME indication) - Continue metformin 500mg BID (not escalating given GI intolerance history) - Diabetic eye exam referral (overdue 2 months — HEDIS measure) - Podiatry referral for initial foot exam - Recheck A1c in 3 months, target <7% 2. Hypertension, Suboptimally Controlled — HCC (when with CKD/DM) - BP today 138/86 — above target of <130/80 (ACC/AHA for DM patients) - Increase lisinopril to 40mg daily - Home BP log review in 4 weeks 3. Major Depressive Disorder, Recurrent, Moderate — HCC 59 - PHQ-9: 14 (moderately severe) — partial response to sertraline 50mg - Increase sertraline to 100mg daily - Safety plan reviewed, crisis line provided (988) - Follow-up in 4 weeks, recheck PHQ-9 - If inadequate response → consider augmentation or psychiatry referral 4. Preventive Care Gaps Addressed: - Mammogram ordered (last: 26 months ago — HEDIS BCS measure) - Colonoscopy referral (age 55, average risk, never screened — HEDIS COL) - Tobacco screening: former smoker, quit 3 years — MIPS measure 226 - Annual flu vaccine administered today — MIPS measure 110
Feature-by-Feature Comparison
Pricing & Access
| Feature | Scribeable | Heidi Health |
|---|---|---|
| Published pricing with dollar amountsheidihealth.com/pricing lists Free, Clinician, and Practice tiers but displays no dollar amounts as of Jul 2026 | ||
| Free tierHeidi's free tier advertises unlimited transcription with standard templates | ||
| Free trial, no card requiredHeidi advertises 14-day trials on its paid tiers; whether a card is required is not stated |
Ownership & Capital
| Feature | Scribeable | Heidi Health |
|---|---|---|
| Clinician-owned, direct-to-clinician accountHeidi is also self-serve for individual clinicians — on this dimension the two are alike | ||
| Zero outside capital (bootstrapped)Heidi announced a $65M USD Series B led by Point72, bringing total funding to roughly $96M |
US Clinical Intelligence
| Feature | Scribeable | Heidi Health |
|---|---|---|
| HCC crosswalk (8,400+ entries) in the noteNot stated on heidihealth.com as of Jul 2026 | ||
| MIPS quality measures scored in the noteNot stated on heidihealth.com as of Jul 2026 | ||
| Deterministic clinical calculators (236, code-scored)Not stated on heidihealth.com as of Jul 2026 |
Competitor facts on this page are sourced to each company's own public site and verified as of 2026-07-11; see page source for the full citation list. Competitor capabilities and pricing may change after that date.
Pricing Comparison
Heidi Health
Free tier plus paid tiers — dollar amounts not displayed on the public pricing page
Contact for pricing
Scribeable's rates are on the pricing page today. Heidi's public pricing page shows tier names and features but no prices as of July 2026; third-party estimates exist but are not confirmed by Heidi itself, so they are not repeated here.
Other AI scribes optimize for time to first draft. Scribeable optimizes for time to signed note, with a verification pass built in before you sign.
5.0 on the App Store120+
Clinicians on board
2,600+
Patient notes generated
Which Should You Choose?
Choose Heidi Health if you...
- Clinicians in Australia, New Zealand, the UK, or Canada, where Heidi advertises regional compliance
- Clinicians who want a free tier with unlimited transcription for basic documentation
- Multi-country groups that need one tool across jurisdictions
Frequently Asked Questions
Compare Other Alternatives
vs Dragon Copilot
Considering Microsoft Dragon Copilot, the product formerly sold as Nuance DAX? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and who each company answers to.
vs Nabla
Considering Nabla? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the "we don't train on your data" promise both companies make.
vs Abridge
Considering Abridge? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the platform.
Start Your 14-Day Free Trial — No Credit Card
Compare Scribeable to Heidi Health on your own terms. Generate your first note in under 5 minutes.
Scribeable vs Heidi Health - AI Medical Scribe Comparison
Considering Heidi? Here is a factual look at how Scribeable differs. Both offer a free tier, so this comparison is about published dollar pricing, US coding depth, and capital structure.
Why Physicians Switch from Heidi Health
- No dollar amounts on the public pricing page — heidihealth.com/pricing shows tiers and features, but seeing a price requires signing up or contacting the team
- US revenue tooling (HCC capture, MIPS scoring) is not advertised on heidihealth.com — worth confirming directly with Heidi if US billing depth matters to your practice
- VC-backed: a $65M Series B led by Point72 sets the growth expectations Heidi answers to
Why Choose Scribeable Over Heidi Health
- $39-79/month, published with dollar amounts — Heidi's public pricing page shows tiers without prices
- HCC crosswalk (8,400+ entries) and MIPS quality measures scored in the note
- 236 clinical calculators, code-scored and validated, inside every note
- A two-stage AI pipeline: a draft pass, then a separate verification pass that asks a clarification question instead of guessing
- 14-day free trial (or 15 notes, whichever comes first), no credit card required
- Zero outside capital — bootstrapped, no VC fund with a future exit to plan around
Built Around US Billing, or Alongside It
Heidi's site advertises compliance across five markets — HIPAA in the US, GDPR, and regional requirements in Australia/NZ, Canada, and the UK. What it does not advertise is US revenue tooling: HCC capture or MIPS quality-measure scoring. Scribeable is built for exactly that — an 8,400+ entry HCC crosswalk and MIPS measures scored inside the note, because for a US practice, the note is where risk-adjusted revenue lives or dies.
Publish the Price or Don't
Heidi's pricing page names its tiers — Free, Clinician, Practice — and lists what each includes. What it doesn't show is a price: no dollar amounts appear on the public page as of July 2026. Scribeable publishes its rates: $39/month for Lite, $79/month for Pro, with a 14-day free trial and no credit card to start. You can see the price before you ever sign up.
A Bootstrapped Cap Table Is a Structural Fact, Not a Slogan
Heidi announced a $65M USD Series B led by Point72 Private Investments — on its own blog — bringing total funding to roughly $96M. Scribeable has raised $0 in outside capital. That difference doesn't say anything about either company's intentions today — it says something about who each company answers to at the next board meeting.
Feature Comparison: Scribeable vs Heidi Health
Pricing & Access
| Feature | Scribeable | Heidi Health |
|---|---|---|
| Published pricing with dollar amounts | Yes | No |
| Free tier | Yes | Yes |
| Free trial, no card required | Yes | Partial |
Ownership & Capital
| Feature | Scribeable | Heidi Health |
|---|---|---|
| Clinician-owned, direct-to-clinician account | Yes | Yes |
| Zero outside capital (bootstrapped) | Yes | No |
US Clinical Intelligence
| Feature | Scribeable | Heidi Health |
|---|---|---|
| HCC crosswalk (8,400+ entries) in the note | Yes | Partial |
| MIPS quality measures scored in the note | Yes | Partial |
| Deterministic clinical calculators (236, code-scored) | Yes | Partial |
Pricing Comparison
Scribeable: Free tier, then $39-79/month, published
Heidi Health: Free tier plus paid tiers — dollar amounts not displayed on the public pricing page
Scribeable's rates are on the pricing page today. Heidi's public pricing page shows tier names and features but no prices as of July 2026; third-party estimates exist but are not confirmed by Heidi itself, so they are not repeated here.
Which Should You Choose?
If US coding depth (HCC, MIPS), published dollar pricing, and a bootstrapped vendor matter to you, that's what Scribeable is built around. If you practice in Australia, New Zealand, the UK, or Canada — or need Heidi's stated regional compliance across those markets — Heidi's international footprint may be the more direct fit.
Frequently Asked Questions
Does Heidi publish its pricing?
Heidi's public pricing page lists its tiers — Free, Clinician, and Practice — but displays no dollar amounts as of July 2026. Scribeable's pricing page lists $39/month (Lite) and $79/month (Pro) directly.
Is Heidi built for US billing?
Heidi advertises HIPAA compliance and US operations. It does not advertise HCC capture or MIPS quality-measure scoring on its public site as of July 2026 — if US risk-adjustment revenue matters to your practice, confirm current capabilities directly with Heidi. Scribeable scores both inside the note.
Is Heidi VC-backed?
Yes. Heidi announced a $65M USD Series B led by Point72 Private Investments (October 2025) on its own blog, with Blackbird, Headline, and Latitude participating; total funding roughly $96M. Scribeable has raised $0 in outside capital.
Both have free tiers — what's the difference?
Heidi's free tier advertises unlimited transcription with standard templates. Scribeable's free tier is 5 notes/month through the same two-stage pipeline as paid plans, and every new account starts with a 14-day full trial (or 15 notes) — no credit card. Run both and compare the notes on your real clinic days.
Sources
Heidi's public pricing page lists Free (unlimited transcription, standard templates), Clinician, and Practice tiers with 14-day trials on the paid tiers, but displays no dollar amounts.
Heidi markets itself as an "AI care partner" and advertises HIPAA, GDPR, and regional compliance for Australia/NZ, Canada, and the UK, plus a free tier with unlimited transcription.
Heidi announced a $65M USD Series B led by Point72 Private Investments (announced October 2025), with Blackbird, Headline, and Latitude participating, bringing total funding to roughly $96M.
Scribeable pricing: Lite $39/mo, Pro $79/mo.
Explore More
Discover how Scribeable can help your practice with AI-powered clinical documentation